The year 2022 marked a pivotal period for Intravacc. We continued our journey towards becoming a leading Contract Development and Manufacturing Organization (CDMO) in the vaccine and immunotherapy industry by focusing on strengthening our commercial and business development capabilities, fostering new partnerships and contracts. Our platform technologies found new applications beyond infectious diseases, broadening our horizons. By optimizing our processes, we delivered best-in-class solutions to our partners more efficiently. We extend our gratitude to our employees, consultants, scientific advisors, shareholders, investors, collaborators, the medical community, the Ministry of Health, and all stakeholders who have supported us. As we look ahead, we are committed to harnessing innovation, continuing to advance vaccine development, and making a lasting impact on global health. Our comprehensive annual report provides a detailed overview of our progress, achievements, and aspirations. Thank you for your continued trust and support as we build Intravacc into a global leading CDMO.